Abstract:Cancer is the second leading cause of mortality worldwide; however the response rate to chemotherapy treatment remains slow, mainly due to narrow therapeutic index and multidrug resistance. Paclitaxel (taxol) has a superior outcome in terms of response rates and progression-free survival. However, numerous cancer patients are resistant to this drug. In this investigation, we tested the hypothesis that induction of cytochrome P450 (Cyp)3a11 gene by paclitaxel is downregulated by the inflammatory mediator, lipopolysaccharide (LPS), and that the pro-inflammatory cytokine, tumor necrosis factor (TNF)-α, attenuates human CYP3A4 gene induction by rifampicin. Primary mouse hepatocytes were pretreated with LPS (1 μg/ml) for 10 min, followed by paclitaxel (20 μM) or vehicle for 24 h. RNA was extracted from the cells by trizol method followed by cDNA synthesis and analysis by real-time PCR. Paclitaxel significantly induced gene expression of Cyp3a11 (~30-fold) and this induction was attenuated in LPS-treated samples. Induction and subsequent downregulation of CYP3A enzyme can impact paclitaxel treatment in cancer patients where inflammatory mediators are activated. It has been shown that the nuclear receptor, pregnane X receptor (PXR), plays a role in the induction of CYP enzymes. In order to understand the mechanisms of regulation of human CYP3A4 gene, we co-transfected HepG2 cells (human liver cell line) with CYP3A4-luciferase construct and a PXR expression plasmid. The cells were then treated with the pro-inflammatory cytokine, TNFα, followed by the prototype CYP3A inducer rifampicin. It is well established that rifampicin activates PXR, leading to CYP3A4 induction. We found that induction of CYP3A4-luciferase activity by rifampicin was significantly attenuated by TNFα. In conclusion, we describe herein several in vitro approaches entailing primary and cultured hepatocytes, real-time PCR, and transcriptional activation (transfection) assays to investigate the molecular regulation of CYP3A, which plays a pivotal role in the metabolism of numerous chemotherapeutic drugs. Genetic or drug-induced variation in CYP3A and/or PXR expression could contribute to drug resistance to chemotherapeutic agents in cancer patients.

Genomic and Proteomic Approaches to Identify Mechanism of Regulation of Cytochrome P450 3a Enzymes

Transcriptomic Profiling Identifies Novel Mechanisms of Transcriptional Regulation of the Cytochrome P450 (cyp)3a11 Gene

Epigenetic Regulation of Cytochrome P450 Enzymes and Clinical Implication

Non-cytochrome P450 enzymes involved in the oxidative metabolism of xenobiotics: Focus on the regulation of gene expression and enzyme activity

Non-cytochrome P450 Enzymes Involved in the Oxidative Metabolism of Xenobiotics: Focus on the Regulation of Gene Expression and Enzyme Activity.

Progress in research of cytochrome P450 3A4 gene polymorphism

Drugs As CYP3A Probes, Inducers, and Inhibitors

In Vitro Approaches to Study Regulation of Hepatic Cytochrome P450 (CYP) 3A Expression by Paclitaxel and Rifampicin

Impact of physiological, pathological and environmental factors on the expression and activity of human cytochrome P450 2D6 and implications in precision medicine.

Molecular Modeling Of Cytochrome P450 And Drug Metabolism

Systematic genetic and genomic analysis of cytochrome P450 enzyme activities in human liver.

Metabolism and Mechanism of Human Cytochrome P450 Enzyme 1A2

Establishing Transcriptional Signatures to Differentiate PXR-, CAR-, and AhR-Mediated Regulation of Drug Metabolism and Transport Genes in Cryopreserved Human Hepatocytes

Insights into the Substrate Specificity, Inhibitors, Regulation, and Polymorphisms and the Clinical Impact of Human Cytochrome P450 1A2

Functional Evaluation of Genetic and Environmental Regulators of P450 Mrna Levels.

Development of Microrna-Dependent Control of Cytochrome P450

Interactions of CYP2C9 with Different Substrates and Its Implications for Metabolic Mechanism

Cytochrome P450 Enzymes and Drug Metabolism in Humans

Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4.

Clinically Important Drug Interactions Potentially Involving Mechanism-based Inhibition of Cytochrome P450 3A4 and the Role of Therapeutic Drug Monitoring

Regulation of Nuclear Receptors on Cytochrome P450 Enzymes